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Letters to the Editor
OBuilt-in bias in HCV clearance in acute
o the Editor:
e read with interest the recent paper about hepatitis C virus
CV) clearance in patients with acute HCV infection [1]. We
re wondering why authors did not calculate risk ratio instead
f odds ratio (OR) when they have run a cohort study? They
an present how much is the incidence of HCV clearance and rel-
tive risk (RR) of factors affecting on such clearance, which is
ore precise than OR and real actual estimation of the strength
f risk factor. Reporting RR besides OR in univariate analysis
nd then multivariable OR based on logistic regression makes it
asy to interpret multivariable (adjusted) OR regarding ‘‘built-
-bias.’’ When the condition of interest has a high incidence
nd prospective data are available, like the study by Mangia
t al. [1], it is usually better to report the RR instead of OR. Imple-
enting OR as an estimate of the RR biases it in a direction oppo-
ite to the null hypothesis; that is, it tends to exaggerate the
agnitude of the association. This is called built-in bias which
negligible when the disease is relatively rare [2]. When the
cidence is high; like spontaneous HCV clearance and
on-responders to treatment in the present study, the bias can
e substantial [2]. In other words, built-in bias is responsible
r the discrepancy between the RR and OR estimates.
The value of this bias is equal to:
1 q
1 qþ
;
hen q+ is the incidence (probability) in exposed and q the inci-
ence in unexposed individuals. For instance, regarding response
treatment and IL28B, 31 out of 40 IL28B CC carriers vs. 27 out of
0 IL28B XT carriers were responder; in this way q+ and q would
e 77.5 and 67.5 percent respectively, indicating built in bias of
.4, which means OR overestimates RR estimation up to 1.4 fold.
egarding relationship between spontaneous HCV clearance and
undice or IL28B, built in bias is lower (about 1.3).
This shows that the value of bias may be considerable in this
tudy and similar researches and we should consider this issue
r future studies as a common mistake which is undertaken by
ost researchers.
Moreover, multivariate OR reported for HCV genotype and
28B (15.6 and 8.7, respectively) as predictors of SVR are not cor-
espondent to the results in the Table 3! Their value cannot be
inﬂuenced very much
such low number of s
the other hand, accor
ment timing (OR 0.9
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o the Editor:
e would like thank our colleagues for their insightful notes on
asic epidemiology. We agree with them that researchers and cli-
icians sometimes forget the different nature of the risk metrics.
Undoubtedly, odds ratios (OR) and relative risks (RR) have differ-
ent deﬁnitions and, therefore, different interpretations. The RR,
computed as the ratio of two risks, is a natural way to compare
risk proportions: a RR of 1.60 indicates a higher risk of 60% in
Journal of Hepatology 2014 vol. 60 j 461–467
pen access under CC BY-NC-ND license.
ese very covariates were strongly unbalanced
oups and the two HCV genotype groups, as
standardized mean differences (an absolute
5% indicates between-group imbalance).
their key role as confounders, which was
he ORs from 1.658 to 8.716, and from 2.987
and HCV genotype, respectively. A key paper
sis for residual confounding serves as refer-
f completeness we also reported in Table 2
, which shows how the ORs moved toward
ore signiﬁcant p values. As a further proof,
ame multivariable model using a Bayesian
lemented in WinBugs, to verify whether in
ch estimation problems occurred. The Bayes-
gression model, which appropriately handles
he adjustment process, provided overlapping
conﬁdence intervals troubled our colleagues.
he two independent predictors, treatment
ce, are continuous variables with their own
must be interpreted consequently. For exam-
atment timing was expressed in weeks and
tivariable analyses, an independent predictor
se with a OR = 0.937 (95% CI = 0.898–0.978,
ress treatment timing in days, the association
1 (95% CI = 0.985–0.997, p = 0.003). On the
e 1
HCV 
genotype 2 + 3
Standardized 
mean difference
-20.85
6) 9 (27.27)
4) 24 (72.73)
 26.33 91.58 ± 26.23 4.34
 13.36 18.01 ± 23.19 30.79
HCV genotype groups.
HCV genotype (2 + 3 vs. 1)
95% CI p value 
0.966-9.232 0.057
1.013-9.990 0.048
1.019-11.564 0.047
1.116-23.442 0.036
2.023-120.45 0.008
Letters to the Editorexposed subjects vs. non-exposed ones to develop an event. The
OR, computed as the ratio of two odds, is a less intuitive risk mea-
sure: an OR of 1.60 does not suggest a higher risk of 60% but a
higher odds in exposed subjects. In our study, the crude OR of
IL28B (exposure) for clearance (outcome) is 4.22 (Table 1), while
the correspondent crude RR is equal to 2.95. The so called built-in
bias could only occur if one reads this OR interpreting it as an RR.
Therefore, why is RR not always used in cohort studies as in our
case? The reason stems from the need to perform a multivariable
analysis in an observational (i.e., non-randomized) study, in
which it is necessary to adjust for potential confounders. To esti-
mate an adjusted RR, binomial or Poisson regressions are usually
used. However, as is commonly known, none of them are satisfac-
tory [1,2]. Convergence problems very often arise with binomial
regression models failing to provide an estimate of RR. While
Poisson regression models provide conservative results (Poisson
distribution is typically used for rare events). Also the conversion
method proposed by the authors has been proven to be invalid
[3]. For these reasons, multivariable logistic regression models,
and therefore the OR, have been widely used and still are even
when events are not rare.
We presented in our original article the well-established
crude and adjusted ORs as the measure of the associations, aware
that Journal of Hepatology readership bears in mind that an OR
must be not interpreted as a RR. In our paper we never discussed
ORs as RRs, and, even when comparisons were reported, they
(see Table 1) that th
in the two IL28B gr
shown by their large
value greater than
Indeed this proves
sufﬁcient to move t
to 15.610, for IL28B
on sensitivity analy
ence [4]. For sake o
the model building
higher values and m
we estimated the s
exact approach, imp
the previous approa
ian exact logistic re
zero cells strata in t
results (Table 3).
Also the ORs 95%
Please note that t
timing and adheren
metrics and results
ple, in our study tre
resulted, in the mul
of treatment respon
p = 0.003). If we exp
results in OR = 0.99
Covariate Category IL28B non-CC IL28B CC Standardized 
mean difference
HCV 
genotyp
Ribavirin use 55.38
No 8 (20.00) 18 (45.00) 17 (36.9
Yes 32 (80.00) 22 (55.00) 29 (63.0
Adherence 90.30 ± 27.32 91.75 ± 24.90 5.55 90.44 ±
Treatment timing 12.66 ± 14.67 16.35 ± 21.07 20.31 12.18 ±
Table 1. Standardized mean difference of ribavirin use, adherence and treatment timing between IL28B and
IL28B CC carriers
Model OR 95% CI p value OR 
A Univariate 1.658 0.614-4.482 0.319 2.987
B Both 1.726 0.609-4.895 0.305 3.181
C B + ribavirin use 2.725 0.809-9.185 0.106 3.433
D C + adherence 3.708 0.844-16.296 0.083 5.116
E D + treatment timing 8.716 1.442-52.674 0.018 15.610
Table 2. Model building for sustained virological response (SVR).referred to crude frequencies and percentages. Multivariable
models were simply used to adjust for potential confounders.
Furthermore, it seems that the results of the multivariable
analysis on sustained virological response (SVR) left the authors
at least perplexed, as the use of the exclamation mark suggests.
However, here we provide some useful epidemiological explana-
tions about confounding. The univariate ORs for IL28B CC carriers
and for HCV genotype were 1.658 and 2.987, respectively. On the
other hand, in the multivariable model, the possible clinical con-
founders, i.e. ribavirin use, adherence and treatment timing,
resulted highly predictive of SVR. Furthermore we observed
other hand, if we express treatment timing in months, the
Variable Median OR 95% CI
IL28B CC carriers 12.450 2.219-106.200
HCV genotype 24.290 3.624-293.800
Ribavirin use 16.720 2.762-149.100
Adherence 1.071 1.036-1.121
Treatment timing 0.934 0.890-0.975
Table 3. Multivariable model for sustained virological response (SVR) esti-
mated using a Bayesian approach.
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association results in OR = 0.753 (95% CI = 0.625–0.907,
p = 0.003). Therefore the narrowness of conﬁdence intervals for
continuous covariates measures of risk is only apparently
misleading.
The authors correctly stated that an imperfect reporting is
present in the manuscript, but not in Table 2 of the original man-
uscript, rather in Table 1, where the absolute counts for ‘‘No jaun-
dice’’ have been inverted between Clearance and Viral Persistence
groups. The corrected numbers are now reported in the following
Table 4.
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Characteristics Overall  
N, (% by column)
Clearance  
N, (% by row)
Viral persistence  
N, (% by row)
p value
Jaundice, n (%) 83 (49.1) 32 (38.6) 51 (61.4) 0.0023
No jaundice, n (%) 86 (50.9) 15 (17.4) 71 (82.6)
Table 4. Correction of Table 1 in ‘‘Mangia A, et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol
2013;59:221–228’’.
How to decide about liver transplantation in patients
with hepatocellular carcinoma: Size and number of lesions
or response to TACE?
To the Editor:
With great interest we read the paper by Otto et al. [1] retrospec-
tively reviewing 136 patients with hepatocellular carcinoma
(HCC) treated with 2 or more cycles of transarterial chemoembol-
isation (TACE) prior to liver transplantation over a period of
13 years. The authors of this single center study suggested that
not preoperative staging (in or out of Milan criteria) but charac-
terisation of tumour response to TACE allows for identiﬁcation of
patients most suitable for liver transplantation by identiﬁcation
of HCC patients with the most favourable tumour biology. The
currently accepted concept of ‘‘downstaging’’ is deﬁned by the
reduction of intrahepatic HCC burden in order to achieve 5-year
survival rates comparable to that of HCC patients to meet trans-
plant criteria without downstaging [2,3]. Therefore, possible
‘‘downstaging’’ by response to TACE should not be confused with
‘‘favourable tumour biology’’.
We agree with the authors that clinical staging for HCC for
‘‘inside’’ or ‘‘outside’’ Milan criteria (MC) may differ in both direc-
tions in up to 25% of cases when compared to histopathology
ﬁndings [4]. However, we believe that critical re-evaluation of
the data presented is needed before response to repeated TACE
can be adopted into clinical decision-making process or for
changing allocation rules.
It seems, even though not clearly stated, that in this analysis
only patients were included who survived the initial in-hospital
phase after liver transplantation. Additionally, no data are
provided on time from diagnosis to listing or waiting times or
drop-outs on the waiting list. No lab-MELD data or match-MELD
data at the time of diagnosis or transplant are provided. Speciﬁ-
cally, it remains unclear whether patients who experienced
downstaging by TACE got the beneﬁt of HCC related match-MELD
or were transplanted only after clinical deterioration or with
expanded criteria donor organs directly allocated to the
transplant center.
Seventy-ﬁve patients (55%) suffered from Child-Pugh A cirrho-
sis, 100 patients had only one or two lesions and/ or 120 out of 136
patients had UICC-T1/T2 tumours. Due to the scarcity of available
organs, liver resection in Child-Pugh A cirrhotic patientsmay have
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